News
Get the latest market insights
Stay up to date with Carbon’s expert perspectives, company news and the latest on the pipeline of novel cell and gene therapies that present profound financial implications for payors.
Follow us on LinkedIn for ongoing updates.
Bluebird’s $2.8M Gene Therapy Becomes Most Expensive Drug
The U.S. Food and Drug Administration on Wednesday approved bluebird bio's (BLUE.O), opens new tab gene therapy for patients with a rare disorder requiring…
Bristol’s Breyanzi Wins Broader FDA Nod, Bringing CAR-T Showdown
The FDA has cleared Bristol Myers’ Breyanzi to treat newly relapsed or refractory large B-cell lymphoma (LBCL). The nod comes less than three months after Yescarta became first…
Medicaid Best Price 101
The lowest price available from the manufacturer during the rebate period to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity…
Yescarta Receives U.S. FDA Approval
Landmark ZUMA-7 Study Demonstrated Patients on Yescarta Were 2.5 Times More Likely to Be Alive at Two Years Without Cancer Progression or Need for…
Carbon Stop Loss Solutions services are provided by IOA Re, LLC (NPN #2006648) and Sequoia Reinsurance Services, LLC (NPN #18853752). Rockport Benefits operates as a division of IOA Re, LLC.